Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase I-II study

Radiotherapy and Oncology

Volumn 88, Issue 1, 2008, Pages 26-33

  Cozzarini, Cesare ^a   Fiorino, Claudio ^a   Di Muzio, Nadia ^a   Valdagni, Riccardo ^b   Salonia, Andrea ^a   Alongi, Filippo ^a   Broggi, Sara ^a   Guazzoni, Giorgio ^a   Montorsi, Francesco ^a   Rigatti, Patrizio ^a   Calandrino, Riccardo ^a   Fazio, Ferruccio ^a,c,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

Adjuvant radiotherapy; Prostate cancer; Radiotherapy planning; Tomotherapy; Toxicity

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CARCINOMA; PROSTATECTOMY; SCORING SYSTEM; SELF REPORT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TOXICITY; URETHRA STRICTURE;

ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOGRAPHY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT OUTCOME;

EID: 45849086912     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.03.021     Document Type: Article

References (43)

1. Hu J.C., Gold K.F., Pashos C.L., Mehta S.S., and Litwin M.S. Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 169 (2003) 1443-1448
2. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
3. Bolla M., Van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
4. Thompson I.M.J., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
5. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
6. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
7. De Meerleer G.O., Villeirs G.M., Vakaet L., Delrue L.J., and De Neve W.J. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer. Strahlenther Onkol 180 (2004) 573-581
8. Bostrom P.J., and Soloway M.S. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk?. Eur Urol 52 (2007) 973-982
9. Brenner D.J., Curtis R.E., Hall E.J., and Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88 (2000) 398-406
10. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
11. Williams S.G., Taylor J.M., Liu N., et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 24-33
12. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
13. Duchesne G.M., and Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44 (1999) 747-748
14. Brenner D.J. Hypofractionation for prostate cancer radiotherapy - what are the issues?. Int J Radiat Oncol Biol Phys 57 (2003) 912-914
15. Kupelian P.A., Reddy C.A., Klein E.A., and Willoughby T.R. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51 (2001) 988-993
16. Grigorov G., Kron T., Wong E., Chen J., Sollazzo J., and Rodrigues G. Optimization of helical tomotherapy treatment plans for prostate cancer. Phys Med Biol 48 (2003) 1933-1943
17. Fowler J.F., Ritter M.A., Chappell R.J., and Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104
18. Marks L.B., Carroll P.R., Dugan T.C., and Anscher M.S. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31 (1995) 1257-1280
19. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
20. Fiorino C., Dell'Oca I., Pierelli A., et al. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol 78 (2006) 276-282
21. van Vulpen M., Field C., Raaijmakers C.P., et al. Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer. Int J Radiat Oncol Biol Phys 62 (2005) 1535-1539
22. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
23. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
24. Forman J.D., Meetze K., Pontes E., et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 158 (1997) 1436-1439
25. Low D.A., Harms W.B., Mutic S., and Purdy J.A. A technique for the quantitative evaluation of dose distributions. Med Phys 25 (1998) 656-661
26. Fiorino C., Foppiano F., Franzone P., et al. Rectal and bladder motion during conformal radiotherapy after radical prostatectomy. Radiother Oncol 74 (2005) 187-195
27. Cappelleri J.C., Rosen R.C., Smith M.D., Mishra A., and Osterloh I.H. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54 (1999) 346-351
28. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., and Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
29. Mebust WK, Roizo R, Schroeder F, Villers A. Correlations between pathology, clinical symptoms and the course of the disease. In: Proceedings of the international consultation on benign prostatic hyperplasia; 1991. p. 53-62.
30. Zelefsky M.J., Aschkenasy E., Kelsen S., and Leibel S.A. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39 (1997) 327-333
31. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol 76 (2005) 1-3
32. Valdagni R., Italia C., Montanaro P., et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 75 (2005) 74-82
33. Vavassori V., Fiorino C., Rancati T., et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 67 (2007) 1401-1410
34. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
35. Kupelian P.A., Thakkar V.V., Khuntia D., Reddy C.A., Klein E.A., and Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
36. Benoit R.M., Naslund M.J., and Cohen J.K. Complications after radical retropubic prostatectomy in the medicare population. Urology 56 (2000) 116-120
37. Popken G., Sommerkamp H., Schultze-Seemann W., Wetterauer U., and Katzenwadel A. Anastomotic stricture after radical prostatectomy. Incidence, findings and treatment. Eur Urol 33 (1998) 382-386
38. Bastasch M.D., Teh B.S., Mai W.Y., et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys 54 (2002) 101-106
39. Shiri R., Ansari M., and Falah H.K. Association between comorbidity and erectile dysfunction in patients with diabetes. Int J Impot Res 18 (2006) 348-353
40. Giuliano F.A., Leriche A., Jaudinot E.O., and de Gendre A.S. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 64 (2004) 1196-1201
41. Ponholzer A., Temml C., Wehrberger C., Marszalek M., and Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol 50 (2006) 581-586
42. Hoeller U., Tribius S., Kuhlmey A., Grader K., Fehlauer F., and Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 55 (2003) 1013-1018
43. van der Laan H.P., Dolsma W.V., Maduro J.H., Korevaar E.W., and Langendijk J.A. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1138-1145